Search Results

Displaying Results 101-125 of 145 "'SLNO'"

Mar 18, 2026, 15:38 ET Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

SLNO) have opportunity to lead the securities fraud class action lawsuit.

More news about: The Law Offices of Frank R. Cruz, Los Angeles


Mar 18, 2026, 11:12 ET Soleno Therapeutics (SLNO) Faces Securities Class Action Amid Hyperphagia Drug Launch Disruptions -- Hagens Berman

SLNO Investors with Losses Encouraged to Contact Hagens BermanSAN FRANCISCO, March 18, 2026 /PRNewswire/ -- A securities class action lawsuit has been filed against Soleno Therapeutics, Inc. (NASDAQ: SLNO) seeking

More news about: Hagens Berman Sobol Shapiro LLP


Mar 18, 2026, 09:50 ET SLNO Investor Alert: Soleno Therapeutics, Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Conducting Sham Clinical Trials: Levi & Korsinsky

March 18, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP reminds purchasers of Soleno Therapeutics, Inc. (NASDAQ: SLNO) securities of a pending securities class action.

More news about: Levi & Korsinsky, LLP


Mar 17, 2026, 09:00 ET SLNO Shareholder Alert: Soleno Therapeutics, Inc. Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm

March 17, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Soleno Therapeutics, Inc. (NASDAQ: SLNO).

More news about: The Gross Law Firm


Mar 16, 2026, 15:06 ET Soleno Therapeutics (SLNO) Faces Securities Class Action Amid Hyperphagia Drug Launch Disruptions -- Hagens Berman

SLNO Investors with Losses Encouraged to Contact the FirmSAN FRANCISCO, March 16, 2026 /PRNewswire/ -- A securities class action lawsuit has been filed against Soleno Therapeutics, Inc. (NASDAQ: SLNO) seeking

More news about: Hagens Berman Sobol Shapiro LLP


Mar 16, 2026, 14:07 ET SLNO INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026

LLP, a leading national securities law firm, is investigating potential claims against Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO) and reminds investors of the May 5, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed

More news about: Faruqi & Faruqi, LLP


Mar 16, 2026, 09:45 ET Soleno Therapeutics Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action - RGRD Law

Robbins Geller Rudman & Dowd LLP announces that purchasers of Soleno Therapeutics, Inc. (NASDAQ: SLNO) common stock between March 26, 2025 and November 4, 2025, both dates inclusive (the "Class Period"), have until May 5, 2026 to seek appointment as lead

More news about: Robbins Geller Rudman & Dowd LLP


Mar 16, 2026, 03:18 ET SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

SLNO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange

More news about: The Schall Law Firm


Mar 16, 2026, 03:03 ET Soleno Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SLNO

SLNO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of SLNO during the class period listed are encouraged

More news about: DJS Law Group LLP


Mar 14, 2026, 17:46 ET Soleno Therapeutics, Inc. (SLNO) Securities Fraud Class Action Lawsuit Filed; May 5, 2026, Lead Plaintiff Deadline

Did you buy SLNO common stock between March 26, 2025, and November 4, 2025?Affected Soleno Therapeutics, Inc. Investor SummaryWho: Soleno Therapeutics, Inc. (

More news about: Kessler Topaz Meltzer & Check, LLP


Mar 13, 2026, 22:14 ET Soleno Therapeutics, Inc. Notice of May 5, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NasdaqCM: SLNO) of a class action securities lawsuit.

More news about: Kahn Swick & Foti, LLC


Mar 12, 2026, 17:00 ET Soleno Therapeutics (SLNO) Faces Securities Class Action Amid Hyperphagia Drug Launch Disruptions -- Hagens Berman

SLNO Investors with Losses Encouraged to Contact Hagens BermanSAN FRANCISCO, March 12, 2026 /PRNewswire/ -- A securities class action lawsuit has been filed against Soleno Therapeutics, Inc. (NASDAQ: SLNO) seeking

More news about: Hagens Berman Sobol Shapiro LLP


Mar 12, 2026, 09:00 ET SLNO Lawsuit Alleges Allegedly Conducting Sham Clinical Trials - Soleno Therapeutics, Inc. Investors Face Losses Following Allegedly Conducting Sham Clinical Trials: SueWallSt

March 12, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP reminds purchasers of Soleno Therapeutics, Inc. (NASDAQ: SLNO) securities of a pending securities class action. THE CASE: A class action seeks to recover damages for investors who purchased Soleno securities

More news about: SueWallSt.com


Mar 12, 2026, 04:40 ET Soleno Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SLNO

SLNO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of SLNO during the class period listed are encouraged

More news about: DJS Law Group LLP


Mar 12, 2026, 04:40 ET SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

SLNO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange

More news about: The Schall Law Firm


Mar 11, 2026, 09:21 ET SLNO SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026

LLP, a leading national securities law firm, is investigating potential claims against Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO) and reminds investors of the May 5, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed

More news about: Faruqi & Faruqi, LLP


Mar 10, 2026, 15:57 ET Soleno Therapeutics (SLNO) Faces Securities Class Action Amid Hyperphagia Drug Launch Disruptions -- Hagens Berman

www.hbsslaw.com/investor-fraud/slnoContact the Firm Now: [email protected]                                       844-916-0895Soleno Therapeutics, Inc. (SLNO) Securities

More news about: Hagens Berman Sobol Shapiro LLP


Mar 09, 2026, 15:23 ET SLNO Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Securities Class Action Against Soleno Therapeutics, Inc.

LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Soleno Therapeutics (NASDAQ: SLNO) common stock between March 26, 2025 and November 4, 2025. Soleno is a pharmaceutical company focused on developing therapies for rare diseases. The

More news about: Robbins LLP


Mar 09, 2026, 15:20 ET SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit

Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 through November 4, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish

More news about: THE ROSEN LAW FIRM, P. A.


Mar 07, 2026, 13:10 ET INVESTOR ALERT: Soleno Therapeutics Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - RGRD Law

Robbins Geller Rudman & Dowd LLP announces that purchasers of Soleno Therapeutics, Inc. (NASDAQ: SLNO) common stock between March 26, 2025 and November 4, 2025, inclusive (the "Class Period"), have until May 5, 2026 to seek appointment as lead plaintiff

More news about: Robbins Geller Rudman & Dowd LLP


Jan 08, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO

2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO). Such investors are advised to contact Danielle Peyton at [email protected] or

More news about: Pomerantz LLP


Jan 01, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO

2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO). Such investors are advised to contact Danielle Peyton at [email protected] or

More news about: Pomerantz LLP


Dec 16, 2025, 12:21 ET Johnson Fistel Begins Investigation on Behalf of Soleno Therapeutics, Inc. (SLNO) Shareholders Who Have Incurred Losses

Dec. 15, 2025 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, PLLP is investigating whether Soleno Therapeutics, Inc. (NASDAQ: SLNO) or certain of its officers and directors violated federal securities laws by making false or misleading statements and/or failing to disclose material

More news about: Johnson Fistel, PLLP


Dec 11, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO

2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO). Such investors are advised to contact Danielle Peyton at [email protected] or

More news about: Pomerantz LLP


Dec 04, 2025, 17:23 ET Johnson Fistel Begins Investigation on Behalf of Soleno Therapeutics, Inc. (SLNO) Shareholders Who Have Incurred Losses

Dec. 4, 2025 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, PLLP is investigating whether Soleno Therapeutics, Inc. (NASDAQ: SLNO) or certain of its officers and directors violated federal securities laws by making false or misleading statements and/or failing to disclose material

More news about: Johnson Fistel, PLLP


Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.